Constitutively active 5-HT2/α1 receptors facilitate muscle spasms after human spinal cord injury

Journal of Neurophysiology

Volumn 109, Issue 6, 2013, Pages 1473-1484

  D'Amico, Jessica M ^a   Murray, Katherine C ^a   Li, Yaqing ^a   Chan, K Ming ^a   Finlay, Mark G ^a   Bennett, David J ^a   Gorassini, Monica A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Inverse agonist; Motoneurons; Norepinephrine; Serotonin; Spasticity

Indexed keywords

CHLORPROMAZINE; CITALOPRAM; CYPROHEPTADINE; NORADRENALIN; SEROTONIN 2 RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; ELECTROMYOGRAPHY; FEMALE; HUMAN; MALE; MOTONEURON; MOTOR PERFORMANCE; MOTOR UNIT; MOTOR UNIT POTENTIAL; MUSCLE SPASM; NERVE CELL EXCITABILITY; NONHUMAN; PRIORITY JOURNAL; RAT; REFLEX; SPINAL CORD INJURY;

ACTION POTENTIALS; ADULT; AGED; BIOGENIC MONOAMINES; CALCIUM; CASE-CONTROL STUDIES; CHLORPROMAZINE; CITALOPRAM; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTOR NEURONS; MUSCLE SPASTICITY; MUSCLE, SKELETAL; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, ADRENERGIC, ALPHA-1; RECRUITMENT, NEUROPHYSIOLOGICAL; REFLEX; SEROTONIN UPTAKE INHIBITORS; SPINAL CORD INJURIES;

EID: 84878499241     PISSN: 00223077     EISSN: 15221598     Source Type: Journal    
DOI: 10.1152/jn.00821.2012     Document Type: Article

References (65)

1. Baker LL, Chandler SH. Characterization of postsynaptic potentials evoked by sural nerve stimulation in hindlimb motoneurons from acute and chronic spinal cats. Brain Res 420: 340-350, 1987.
2. Barbeau H, Filion M, Bedard P. Effects of agonists and antagonists of serotonin on spontaneous hindlimb EMG activity in chronic spinal rats. Neuropharmacology 20: 99-107, 1981.
3. Basmajian JV, Szatmari A. Effect of Largactil (chlorpromazine) on human spasticity and electromyogram. Arch Neurol Psychiatry 73A: 224-231, 1955.
4. Bennett DJ, Li Y, Siu M. Plateau potentials in sacrocaudal motoneurons of chronic spinal rats, recorded in vitro. J Neurophysiol 86: 1955-1971, 2001.
5. Bezchlibnyk-Butler K, Aleksic I, Kennedy SH. Citalopram-a review of pharmacological and clinical effects. J Psychiatry Neurosci 25: 241-254, 2000.
6. Boess FG, Martin IL. Molecular biology of 5-HT receptors. Neuropharmacology 33: 275-317, 1994.
7. Bonhaus DW, Weinhardt KK, Taylor M, DeSouza A, McNeeley PM, Szczepanski K, Fontana DJ, Trinh J, Rocha CL, Dawson MW, Flippin LA, Eglen RM. RS-102221: a novel high affinity and selective 5-HT2C receptor antagonist. Neuropharmacology 36: 621-629, 1997.
8. Boulenguez P, Liabeuf S, Bos R, Bras H, Jean-Xavier C, Brocard C, Stil A, Darbon P, Cattaert D, Delpire E, Marsala M, Vinay L. Downregulation of the potassium-chloride cotransporter KCC2 contributes to spasticity after spinal cord injury. Nat Med 16: 302-307, 2010.
9. Cohan SL, Raines A, Panagakos J, Arimitage P. Phenytoin and chlorpromazine in the treatment of spasticity. Arch Neurol 37: 360-364, 1980.
10. Curtis DR, Gynther BD, Lacey G, Beattie DT. Baclofen: reduction of presynaptic calcium influx in the cat spinal cord in vivo. Exp Brain Res 113: 520-533, 1997.
11. D'Amico J, Li Y, Bennett DJ, Gorassini MA. Reduction of spinal sensory transmission by facilitation of 5-HT1B/D receptors in noninjured and spinal cord-injured humans. J Neurophysiol (December 5, 2012). doi:10.1152/ jn.00822.2012.
12. Dai Y, Carlin KP, Li Z, McMahon DG, Brownstone RM, Jordan LM. Electrophysiological and pharmacological properties of locomotor activityrelated neurons in cfos-EGFP mice. J Neurophysiol 102: 3365-3383, 2009.
13. Ellingson BM, Ulmer JL, Kurpad SN, Schmit BD. Diffusion tensor MR imaging in chronic spinal cord injury. AJNR Am J Neuroradiol 29: 1976-1982, 2008.
14. Gorassini MA, Yang JF, Siu M, Bennett DJ. Intrinsic activation of human motoneurons: possible contribution to motor unit excitation. J Neurophysiol 87: 1850-1858, 2002.
15. Gorassini MA, Knash ME, Harvey PJ, Bennett DJ, Yang JF. Role of motoneurons in the generation of muscle spasticity after spinal cord injury. Brain 127: 2247-58, 2004.
16. Gracies JM, Nance P, Elovic E, McGuire J, Simpson DM. Traditional pharmacological treatments for spasticity. Part II: General and regional treatments. Muscle Nerve Suppl 6: S92-S120, 1997.
17. Harvey PJ, Li X, Li Y, Bennett DJ. 5-HT2 receptor activation facilitates a persistent sodium current and repetitive firing in spinal motoneurons of rats with and without chronic spinal cord injury. J Neurophysiol 96: 1158-1170, 2006a.
18. Harvey PJ, Li X, Li Y, Bennett DJ. Endogenous monoamine receptor activation is essential for enabling persistent sodium currents and repetitive firing in rat spinal motoneurons. J Neurophysiol 96: 1171-1186, 2006b.
19. Heckman CJ, Lee RH, Brownstone RM. Hyperexcitable dendrites in motoneurons and their neuromodulatory control during motor behaviour. Trends Neurosci 26: 688-695, 2003.
20. Herrick-Davis K, Grinde E, Teitler M. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J Pharmacol Exp Ther 295: 226-232, 2000.
21. Holstege JC, Kuypers HG. Brainstem projections to spinal motoneurons: an update. Neuroscience 23: 809-821, 1987.
22. Hounsgaard J, Hultborn H, Jespersen B, Kiehn O. Bistability of alphamotoneurons in the decerebrate cat and in the acute spinal cat after intravenous 5-hydroxytryptophan. J Physiol 405: 345-367, 1988.
23. Hsiao CF, Wu N, Chandler SH. Voltage-dependent calcium currents in trigeminal motoneurons of early postnatal rats: modulation by 5-HT receptors. J Neurophysiol 94: 2063-2072, 2005.
24. Hyttel J. Citalopram-pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry 6: 277-295, 1982.
25. Ito T, Furukawa K, Karasawa T, Kadokawa T, Shimizu M. Effects of chlorpromazine, imipramine and baclofen on the spinal polysynaptic reflex in acute, chronic and 6-hydroxydopamine-treated spinal rats. Jpn J Pharmacol 32: 1125-1133, 1982.
26. Jacobs BL, Martin-Cora FJ, Fornal CA. Activity of medullary serotonergic neurons in freely moving animals. Brain Res Rev 40: 45-52, 2002.
27. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28: 519-526, 2003.
28. Lazorthes Y, Sallerin-Caute B, Verdie JC, Bastide R, Carillo JP. Chronic intrathecal baclofen administration for control of severe spasticity. J Neurosurg 72: 393-402, 1990.
29. Li Y, Bennett DJ. Persistent sodium and calcium currents cause plateau potentials in motoneurons of chronic spinal rats. J Neurophysiol 90: 857-869, 2003.
30. Li Y, Gorassini MA, Bennett DJ. Role of persistent sodium and calcium currents in motoneuron firing and spasticity in chronic spinal rats. J Neurophysiol 91: 767-783, 2004a.
31. Li Y, Li X, Harvey PJ, Bennett DJ. Effects of baclofen on spinal reflexes and persistent inward currents in motoneurons of chronic spinal rats with spasticity. J Neurophysiol 92: 2694-2703, 2004b.
32. Martin GR. Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine. Cephalalgia 17, Suppl 18: 4-14, 1997.
33. Martin RF, Jordan LM, Willis WD. Differential projections of cat medullary raphe neurons demonstrated by retrograde labelling following spinal cord lesions. J Comp Neurol 182: 77-88, 1978.
34. Mendes GD, Arruda A, Chen LS, de Almeida Magalhaes JC, Alkharfy KM, De Nucci M. Quantification of cyproheptadine in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry in a bioequivalence study. Biomed Chromatogr 26: 129-136, 2012.
35. Miles GB, Hartley R, Todd AJ, Brownstone RM. Spinal cholinergic interneurons regulate the excitability of motoneurons during locomotion. Proc Natl Acad Sci USA 104: 2448-2453, 2007.
36. Mizuno N, Itoh H. Functions and regulatory mechanisms of Gq-signaling pathways. Neurosignals 17: 42-54, 2009.
37. Moguilevsky N, Varsalona F, Noyer M, Gillard M, Guillaume JP, Garcia L, Szpirer C, Szpirer J, Bollen A. Stable expression of human H1histamine-receptor cDNA in Chinese hamster ovary cells: pharmacological characterisation of the protein, tissue distribution of messenger RNA and chromosomal localisation of the gene. Eur J Biochem 224: 489-495, 1994.
38. Murray KC, Stephens MJ, Rank M, D'Amico J, Gorassini MA, Bennett DJ. Polysynaptic excitatory postsynaptic potentials that trigger spasms after spinal cord injury in rats are inhibited by 5-HT1B and 5-HT1F receptors. J Neurophysiol 106: 925-943, 2011a.
39. Murray KC, Stephens MJ, Ballou EW, Heckman CJ, Bennett DJ. Motoneuron excitability and muscle spasms are regulated by 5-HT2B and 5-HT2C receptor activity. J Neurophysiol 105: 731-748, 2011b.
40. Murray KC, Nakae A, Stephens MJ, Rank M, D'Amico JM, Harvey PJ, Li X, Harris RL, Ballou EW, Anelli R, Heckman CJ, Mashimo T, Vavrek R, Sanelli L, Gorassini MA, Bennett DJ, Fouad K. Recovery of motoneuron and locomotor function after spinal cord injury depends on constitutive activity in 5-HT2C receptors. Nat Med 16: 694-700, 2010.
41. Nance PW. A comparison of clonidine, cyproheptadine and baclofen in spastic spinal cord injured patients. J Am Paraplegia Soc 17: 150-156, 1994.
42. Nathan PW. Effects on movement of surgical incisions into the human spinal cord. Brain 117: 337-346, 1994.
43. Nielsen JF, Hansen HJ, Sunde N, Christensen JJ. Evidence of tolerance to baclofen in treatment of severe spasticity with intrathecal baclofen. Clin Neurol Neurosurg 104: 142-145, 2002.
44. Norton JA, Bennett DJ, Knash ME, Murray KC, Gorassini MA. Changes in sensory-evoked synaptic activation of motoneurons after spinal cord injury in man. Brain 131: 1478-1491, 2008.
45. Perrier JF, Alaburda A, Hounsgaard J. Spinal plasticity mediated by postsynaptic L-type Ca channels. Brain Res Rev 40: 223-229, 2002.
46. Perrier JF, Cotel F. Serotonin differentially modulates the intrinsic properties of spinal motoneurons from the adult turtle. J Physiol 586: 1233-1238, 2008.
47. Petersen JA, Wilm BJ, von Meyenburg J, Schubert M, Seifert B, Najafi Y, Dietz V, Kollias S. Chronic cervical spinal cord injury: DTI correlates with clinical and electrophysiological measures. J Neurotrauma 29: 1556-1566, 2012.
48. Rank MM, Murray KC, Stephens MJ, D'Amico J, Gorassini MA, Bennett DJ. Adrenergic receptors modulate motoneuron excitability, sensory synaptic transmission and muscle spasms after chronic spinal cord injury. J Neurophysiol 105: 410-422, 2011.
49. Rauser L, Savage JE, Meltzer HY, Roth BL. Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5HT2C receptor. J Pharmacol Exp Ther 299: 83-89, 2001.
50. Richelson E. Neuroleptic binding to human brain receptors: relation to clinical effects. Ann NY Acad Sci 537: 435-442, 1988.
51. Richelson E, Nelson A. Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. Eur J Pharmacol 103: 197-204, 1984.
52. Roby-Brami A, Bussel B. Long-latency spinal reflex in main after flexor reflex afferent stimulation. Brain 110: 707-725, 1987.
53. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268: 1403-1410, 1994.
54. Seeman P, Corbett R, Van Tol HH. Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology 16: 93-110, 1997.
55. Stanton T, Bolden-Watson C, Cusack B, Richelson E. Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics. Biochem Pharmacol 45: 2352-2354, 1993.
56. Stempien L, Tsai T. Intrathecal baclofen pump use for spasticity: a clinical survey. Am J Phys Med Rehabil 79: 536-541, 2000.
57. Stormann TM, Gdula DC, Weiner DM, Brann MR. Molecular cloning and expression of a dopamine D2 receptor from human retina. Mol Pharmacol 37: 1-6, 1990.
58. Thompson CK, Jayaraman A, Kinnaird C, Hornby TG. Methods to quantify pharmacologically induced alterations in motor function in human incomplete SCI. J Vis Exp 50: 2148, 2011.
59. Toll L, Berzetei-Gurske IP, Polgar WE, Brandt SR, Adapa ID, Rodriguez L, Schwartz RW, Haggart D, O'Brien A, White A, Kennedey JM, Craymer K, Farrington L, Auh JS. Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res Monogr 178: 440-466, 1998.
60. Tóth K, Szönyi A. The appetite stimulating and weight gain promoting effect of Peritol (cyproheptadine) examined on a great number of outpatients. Ther Hung 24: 24-32, 1976.
61. Udina E, D'Amico J, Bergquist AJ, Gorassini MA. Amphetamine increases persistent inward currents in human motoneurons estimated from paired motor unit activity. J Neurophysiol 103: 1295-1303, 2010.
62. Wainberg M, Barbeau H, Gauthier S. The effects of cyproheptadine on locomotion and on spasticity in patients with spinal cord injuries. J Neurol Neurosurg Psychiatry 53: 754-763, 1990.
63. Yeung PKF, Hubbard JW, Korchinski ED, Midha KK. Pharmacokinetics of chlorpromazine and key metabolites. Eur J Clin Pharmacol 45: 563-569, 1993.
64. Yoshio R, Taniguchi T, Itoh H, Muramatsu I. Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes. Jpn J Pharmacol 86: 189-195, 2001.
65. Ziemann U. TMS and drugs. Clin Neurophysiol 115: 1717-1729, 2004.